Key Points
- CEO Robert Ainscow sold 25,000 shares of ASP Isotopes on Nov. 25 at an average price of $5.77 for $144,250, leaving him with 1,554,693 shares (a 1.58% ownership reduction); the trade was disclosed in an SEC Form 4 filing.
- Ainscow has been actively selling recently — a total of 123,438 shares between Sept. and Nov. (about $1.03M in proceeds), signaling a clear pattern of insider selling.
- ASP Isotopes is trading below its recent averages (50-day $9.08, 200-day $8.81), has a market cap of ~$618M and negative EPS and very large negative margins
ASP Isotopes Inc. (NASDAQ:ASPI - Get Free Report) CEO Robert Ainscow sold 25,000 shares of the business's stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $5.77, for a total value of $144,250.00. Following the transaction, the chief executive officer owned 1,554,693 shares in the company, valued at approximately $8,970,578.61. This trade represents a 1.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Robert Ainscow also recently made the following trade(s):
- On Monday, November 17th, Robert Ainscow sold 67,500 shares of ASP Isotopes stock. The shares were sold at an average price of $7.51, for a total value of $506,925.00.
- On Tuesday, October 14th, Robert Ainscow sold 22,500 shares of ASP Isotopes stock. The stock was sold at an average price of $13.60, for a total value of $306,000.00.
- On Monday, September 8th, Robert Ainscow sold 8,438 shares of ASP Isotopes stock. The shares were sold at an average price of $8.53, for a total transaction of $71,976.14.
ASP Isotopes Stock Performance
Shares of ASP Isotopes stock opened at $5.58 on Tuesday. The company has a 50 day moving average price of $9.08 and a 200 day moving average price of $8.81. The firm has a market capitalization of $618.49 million, a P/E ratio of -4.29 and a beta of 3.42. The company has a quick ratio of 6.10, a current ratio of 6.14 and a debt-to-equity ratio of 1.04. ASP Isotopes Inc. has a 52 week low of $3.65 and a 52 week high of $14.49.
ASP Isotopes (NASDAQ:ASPI - Get Free Report) last issued its quarterly earnings results on Wednesday, November 19th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.05). The company had revenue of $4.89 million for the quarter, compared to analyst estimates of $2.25 million. ASP Isotopes had a negative net margin of 1,259.12% and a negative return on equity of 190.44%. Sell-side analysts expect that ASP Isotopes Inc. will post -0.24 EPS for the current year.
Hedge Funds Weigh In On ASP Isotopes
A number of institutional investors have recently modified their holdings of ASPI. Quantbot Technologies LP purchased a new stake in shares of ASP Isotopes in the third quarter worth about $34,000. Ameritas Investment Partners Inc. boosted its position in ASP Isotopes by 41.2% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,483 shares of the company's stock worth $40,000 after purchasing an additional 1,600 shares in the last quarter. BNP Paribas Financial Markets grew its stake in shares of ASP Isotopes by 84.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company's stock worth $41,000 after purchasing an additional 2,548 shares during the period. Close Asset Management Ltd acquired a new stake in shares of ASP Isotopes during the 3rd quarter worth approximately $72,000. Finally, Tower Research Capital LLC TRC increased its holdings in shares of ASP Isotopes by 96.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 10,890 shares of the company's stock valued at $80,000 after purchasing an additional 5,353 shares in the last quarter. Hedge funds and other institutional investors own 16.80% of the company's stock.
Analysts Set New Price Targets
A number of equities analysts recently issued reports on ASPI shares. Canaccord Genuity Group restated a "buy" rating and issued a $11.00 target price on shares of ASP Isotopes in a research note on Monday, November 24th. Loop Capital set a $15.00 price objective on ASP Isotopes in a research note on Monday, October 27th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of ASP Isotopes in a report on Tuesday, November 25th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $13.00.
View Our Latest Research Report on ASP Isotopes
About ASP Isotopes
(
Get Free Report)
ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
